Acquired Orphan Blood Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
250 Pages
December 2023
Region: Global
Fairfield Market Research
ID: 5922717

The global acquired orphan blood disease market is poised for substantial growth over the forecast period. The market is projected to reach a valuation of US$ 21 billion by 2031, a significant increase from US$ 8.4 billion in 2024. North America is expected to maintain its leading position in the market throughout the forecast period from 2024 to 2031.

Market Evolution:

Rising Incidence of Chronic Diseases:

The global market for acquired orphan blood diseases is witnessing growth due to the increasing prevalence of chronic diseases worldwide.
Growing awareness of healthcare and technological advancements in the medical industry are driving demand for healthcare solutions.

Increasing Per Capita Income in Developing Nations:

Rising per capita income in developing countries is boosting their ability to spend on advanced healthcare solutions.
This trend is expected to contribute to increased sales opportunities in the global market.

Emergence of Novel Therapies:

The introduction of novel therapies is creating new growth opportunities for industry players.
Emerging markets like India are anticipated to offer growth prospects in the market.

Challenges to Market Growth:

Longer Drug Approval Duration:

Drug approval in the acquired blood disease market is a time-consuming process, which may restrict growth opportunities.
Stringent regulatory policies and limited investments in rare diseases pose challenges for market expansion.

Rising Consolidations:

An increasing number of consolidations may hinder the entry of new players into the market.

Dominating Regional Position:

Increasing Prevalence in North America:

North America is expected to maintain its dominant position in the market due to the rising incidence of blood-related diseases in the region.
Increased research and development investments and improved access to healthcare insurance facilities, especially in the U.S., are influencing growth opportunities.

Growth in Europe:

Europe is expected to witness significant growth, driven by its well-structured and advanced healthcare solutions.

Rapid Growth in Asia:

East Asia and South Asia & Pacific regions are projected to experience rapid growth, supported by government initiatives for effective healthcare facilities and infrastructure development.

Market Overview:

Acquired orphan blood diseases result from a lack of blood components, including red blood cells, white blood cells, and platelets. These conditions, such as anemia, leucopenia, and thrombocytopenia, are characterized by symptoms like fatigue, weakness, fever, infections, and bleeding.

Acquired orphan blood diseases, like Paroxysmal Nocturnal Hemoglobinuria (PNH), Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), and Polycythemia Vera (PV), are caused by insufficient red blood cell production and improper bone marrow function. They often result in anemia and thrombosis.

Treatment options include medication, bone marrow transplants, blood transfusions, and iron therapy.

Key Market Players:

Alexion Pharmaceuticals, Inc.
Amgen, Inc.
Celgene Corporation
Eli Lilly and Company
Sanofi S.A.
GlaxoSmithKline plc.
Cyclacel Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
Incyte Corporation
CTI BioPharma Corp.

Acquired Orphan Blood Disease Industry Research by Category

By Therapy:

Recombinant Factor
Immunoglobulin Infusion Therapy
Activated Prothrombin Complex Concentrate
Thrombopoietin Receptor Agonists
Others

By Disease Indication:

Acquired Agranulocytosis
Acquired Hemophilia
Acquired Von Willebrand Syndrome
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic Syndrome
Other

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Others

By Region:

North America
Europe
Latin America
East Asia
The Middle East & Africa
South Asia & Pacific

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Acquired Orphan Blood Disease Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Acquired Orphan Blood Disease Market Outlook, 2018 - 2031

3.1. Global Acquired Orphan Blood Disease Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Recombinant Factor
3.1.1.2. Immunoglobulin Infusion Therapy
3.1.1.3. Activated Prothrombin Complex Concentrate
3.1.1.4. Thrombopoietin Receptor Agonists
3.1.1.5. Others
3.2. Global Acquired Orphan Blood Disease Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Acquired Agranulocytosis
3.2.1.2. Acquired Hemophilia
3.2.1.3. Acquired Von Willebrand Syndrome
3.2.1.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
3.2.1.5. Myelodysplastic Syndrome
3.2.1.6. Other
3.3. Global Acquired Orphan Blood Disease Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacy
3.3.1.2. Retail Pharmacy
3.3.1.3. Others
3.4. Global Acquired Orphan Blood Disease Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Acquired Orphan Blood Disease Market Outlook, 2018 - 2031

4.1. North America Acquired Orphan Blood Disease Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Recombinant Factor
4.1.1.2. Immunoglobulin Infusion Therapy
4.1.1.3. Activated Prothrombin Complex Concentrate
4.1.1.4. Thrombopoietin Receptor Agonists
4.1.1.5. Others
4.2. North America Acquired Orphan Blood Disease Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Acquired Agranulocytosis
4.2.1.2. Acquired Hemophilia
4.2.1.3. Acquired Von Willebrand Syndrome
4.2.1.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
4.2.1.5. Myelodysplastic Syndrome
4.2.1.6. Other
4.3. North America Acquired Orphan Blood Disease Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacy
4.3.1.2. Retail Pharmacy
4.3.1.3. Others
4.4. North America Acquired Orphan Blood Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Acquired Orphan Blood Disease Market Outlook, 2018 - 2031

5.1. Europe Acquired Orphan Blood Disease Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Recombinant Factor
5.1.1.2. Immunoglobulin Infusion Therapy
5.1.1.3. Activated Prothrombin Complex Concentrate
5.1.1.4. Thrombopoietin Receptor Agonists
5.1.1.5. Others
5.2. Europe Acquired Orphan Blood Disease Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Acquired Agranulocytosis
5.2.1.2. Acquired Hemophilia
5.2.1.3. Acquired Von Willebrand Syndrome
5.2.1.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
5.2.1.5. Myelodysplastic Syndrome
5.2.1.6. Other
5.3. Europe Acquired Orphan Blood Disease Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacy
5.3.1.2. Retail Pharmacy
5.3.1.3. Others
5.4. Europe Acquired Orphan Blood Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acquired Orphan Blood Disease Market Outlook, 2018 - 2031

6.1. Asia Pacific Acquired Orphan Blood Disease Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Recombinant Factor
6.1.1.2. Immunoglobulin Infusion Therapy
6.1.1.3. Activated Prothrombin Complex Concentrate
6.1.1.4. Thrombopoietin Receptor Agonists
6.1.1.5. Others
6.2. Asia Pacific Acquired Orphan Blood Disease Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Acquired Agranulocytosis
6.2.1.2. Acquired Hemophilia
6.2.1.3. Acquired Von Willebrand Syndrome
6.2.1.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
6.2.1.5. Myelodysplastic Syndrome
6.2.1.6. Other
6.3. Asia Pacific Acquired Orphan Blood Disease Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacy
6.3.1.2. Retail Pharmacy
6.3.1.3. Others
6.4. Asia Pacific Acquired Orphan Blood Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acquired Orphan Blood Disease Market Outlook, 2018 - 2031

7.1. Latin America Acquired Orphan Blood Disease Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Recombinant Factor
7.1.1.2. Immunoglobulin Infusion Therapy
7.1.1.3. Activated Prothrombin Complex Concentrate
7.1.1.4. Thrombopoietin Receptor Agonists
7.1.1.5. Others
7.2. Latin America Acquired Orphan Blood Disease Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Acquired Agranulocytosis
7.2.1.2. Acquired Hemophilia
7.2.1.3. Acquired Von Willebrand Syndrome
7.2.1.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
7.2.1.5. Myelodysplastic Syndrome
7.2.1.6. Other
7.3. Latin America Acquired Orphan Blood Disease Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacy
7.3.1.2. Retail Pharmacy
7.3.1.3. Others
7.4. Latin America Acquired Orphan Blood Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acquired Orphan Blood Disease Market Outlook, 2018 - 2031

8.1. Middle East & Africa Acquired Orphan Blood Disease Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Recombinant Factor
8.1.1.2. Immunoglobulin Infusion Therapy
8.1.1.3. Activated Prothrombin Complex Concentrate
8.1.1.4. Thrombopoietin Receptor Agonists
8.1.1.5. Others
8.2. Middle East & Africa Acquired Orphan Blood Disease Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Acquired Agranulocytosis
8.2.1.2. Acquired Hemophilia
8.2.1.3. Acquired Von Willebrand Syndrome
8.2.1.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
8.2.1.5. Myelodysplastic Syndrome
8.2.1.6. Other
8.3. Middle East & Africa Acquired Orphan Blood Disease Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacy
8.3.1.2. Retail Pharmacy
8.3.1.3. Others
8.4. Middle East & Africa Acquired Orphan Blood Disease Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Acquired Orphan Blood Disease Market by Therapy, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Acquired Orphan Blood Disease Market by Disease Indication, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Acquired Orphan Blood Disease Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Therapy vs Disease Indication Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Alexion Pharmaceuticals, Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Amgen, Inc.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Celgene Corporation
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Eli Lilly and Company
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Sanofi S.A.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. GlaxoSmithKline plc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Cyclacel Pharmaceuticals, Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Onconova Therapeutics, Inc
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Incyte Corporation
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Incyte Corporation
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Alexion Pharmaceuticals, Inc.
Amgen, Inc.
Celgene Corporation
Eli Lilly and Company
Sanofi S.A.
GlaxoSmithKline plc.
Cyclacel Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
Incyte Corporation
CTI BioPharma Corp.

Methodology

LOADING...